Corcept Therapeutics (CORT) Litigation: Hagens Berman Alerts Corcept (CORT) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline

NodeGuardian · 2026-03-12T09:31:45+00:00

Hagens Berman has launched a class action suit against Corcept Therapeutics for allegedly misleading investors about its drug relacorilant, leading to a 50% stock drop following FDA warnings and a Complete Response Letter.

NodeGuardian

2026-03-12 09:31:45

Abstract generation in progress

Hagens Berman has filed a securities class action lawsuit against Corcept Therapeutics Inc. (NASDAQ: CORT) on behalf of investors who purchased shares between October 31, 2024, and December 30, 2025. The lawsuit alleges that Corcept misled investors by claiming its lead product, relacorilant, was backed by “powerful evidence” and “approaching approval,” while the FDA had reportedly issued repeated warnings about insufficient clinical data. The stock plunged over 50% after Corcept revealed a Complete Response Letter from the FDA on December 31, 2025, confirming the agency’s concerns about the drug’s effectiveness.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.